# Crescent Gene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/crescent-gene

- Industry: Biotechnology
- Headquarters: China
- Total disclosed funding: $60M
- Latest round: Series B (Jan 5, 2022)
- Investors on record: 4

## About

Based in China, Crescent Gene operates as a biopharmaceutical technology company that provides solid tumor cell therapy products enable to enhance the treatment process of tumor patients. In January 2022, Crescent Gene raised USD 60 million in a Series B funding led by Shanghui Investment, with participation from Yuanhe Fund, Qiming Venture Partners, and Blue Ocean Capital.

## Funding rounds

- Series B, Jan 5, 2022, $60M — Qiming Venture Partners, Blue Ocean Capital, Yuanhe Fund, Shanghui Investment

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B
- Blue Ocean Capital (https://capitalatlas.ai/funds/blue-ocean-capital) — Series B
- Yuanhe Fund — Series B
- Shanghui Investment — Series B